Media coverage about Leap Therapeutics (NASDAQ:LPTX) has trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Leap Therapeutics earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.5265673083678 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Leap Therapeutics (LPTX) traded down 3.10% during mid-day trading on Friday, reaching $5.63. 22,699 shares of the company were exchanged. Leap Therapeutics has a 1-year low of $5.40 and a 1-year high of $10.10. The stock’s 50-day moving average price is $6.50 and its 200-day moving average price is $7.15. The stock’s market capitalization is $52.89 million.

Leap Therapeutics (NASDAQ:LPTX) last released its earnings results on Friday, August 11th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.71) by $0.03. On average, equities research analysts anticipate that Leap Therapeutics will post ($3.16) EPS for the current fiscal year.

Separately, Zacks Investment Research raised shares of Leap Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, May 30th.

COPYRIGHT VIOLATION NOTICE: “Leap Therapeutics (LPTX) Earning Somewhat Favorable Press Coverage, Analysis Shows” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at

About Leap Therapeutics

Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).

Receive News & Ratings for Leap Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.